← Russell 3000 cross-section

KRYS Krystal Biotech, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-03, not restated
Healthcare

Scale

Market cap
$10.7bn
Revenue TTM
$440m
Net income TTM
$242m
Free cash flow
$258m
Composite score
54.4
Sector rank
#680

Valuation

P / E
44.4
EV / EBITDA
48.5
EV / sales
22.4
FCF yield
2.40%
Earnings yield vs 10-yr
-2.48pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
54.8%
EBITDA margin
46.3%
ROE
17.8%
ROIC
38.5%
Revenue growth
22.6%

Insider activity, last 90 days

Net open-market
$-23.98m
Buyers
0
Sellers
4

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Net VYJUVEK product revenue was $119.2 million for the three months ended June 30, 2026, and $965.9 million in cumulative net product revenue since our first launch of VYJUVEK in the United States in 2023. Gross margin for the three months ended June 30, 2026 was 95%. Three Months Ended June 30, 2026 and 2025 Product Revenue, Net Product revenue, net was $119.2 million for the three months ended June 30, 2026, as compared to $96.0 million for the three months ended June 30, 2025. …Krystal Biotech, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-03

Read the full passage →